COVID-19 vaccine trial ethics once we have efficacious vaccines.

Wendler, David; Ochoa, Jorge; Millum, Joseph; Grady, Christine; Taylor, Holly A

Wendler, David; Ochoa, Jorge; Millum, Joseph; Grady, Christine; Taylor, Holly A.

Wendler D; Department of Bioethics, National Institutes of Health (NIH) Clinical Center, Bethesda, MD, USA. dwendler@nih.gov.
Ochoa J; Department of Bioethics, National Institutes of Health (NIH) Clinical Center, Bethesda, MD, USA.
Millum J; Department of Bioethics, National Institutes of Health (NIH) Clinical Center, Bethesda, MD, USA.
Grady C; Fogarty International Center, NIH, Bethesda, MD, USA.
Taylor HA; Department of Bioethics, National Institutes of Health (NIH) Clinical Center, Bethesda, MD, USA.

Science ; 370(6522): 1277-1279, 2020 12 11.

Article in English | MEDLINE | ID: covidwho-2305628

Subject(s)

COVID-19 Vaccines/adverse effects; COVID-19 Vaccines/therapeutic use; Controlled Clinical Trials as Topic/ethics; Drug Approval; Healthy Volunteers; Humans; Placebos; Risk Assessment; United States; United States Food and Drug Administration

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Controlled Clinical Trials as Topic / COVID-19 Vaccines Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Science Year: 2020 Document Type: Article Affiliation country: Science.abf5084

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google